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Abstract
Introduction: Excessive bleeding (EB) after cardiopulmonary bypass (CPB) may lead to increased
mortality, morbidity, transfusion requirements and re-intervention. Less than 50% of patients
undergoing re-intervention exhibit surgical sources of bleeding. We studied clinical and genetic
factors associated with EB.
Methods:  We performed a nested case-control study of 26 patients who did not receive
antifibrinolytic prophylaxis. Variables were collected preoperatively, at intensive care unit (ICU)
admission, at 4 and 24 hours post-CPB. EB was defined as 24-hour blood loss of >1 l post-CPB.
Associations of EB with genetic, demographic, and clinical factors were analyzed, using SPSS-12.2
for statistical purposes.
Results: EB incidence was 50%, associated with body mass index (BMI)< 26.4 (25–28) Kg/m2, (P =
0.03), lower preoperative levels of plasminogen activator inhibitor-1 (PAI-1) (P = 0.01), lower body
temperature during CPB (P = 0.037) and at ICU admission (P = 0.029), and internal mammary artery
graft (P  = 0.03) in bypass surgery. We found a significant association between EB and 5G
homozygotes for PAI-1, after adjusting for BMI (F = 6.07; P = 0.02) and temperature during CPB (F
= 8.84; P = 0.007). EB patients showed higher consumption of complement, coagulation, fibrinolysis
and hemoderivatives, with significantly lower leptin levels at all postoperative time points (P = 0.01,
P < 0.01 and P < 0.01).
Conclusion: Excessive postoperative bleeding in CPB patients was associated with demographics,
particularly less pronounced BMI, and surgical factors together with serine protease activation.
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Background
When blood interacts with non-endothelial surfaces of
the cardiopulmonary bypass machine, cellular and
humoral pathways are activated, including the comple-
ment system, the coagulation system, and the fibrinolytic
system. These in turn activate inflammatory response cells
such as leukocytes and platelets. Together these molecular
pathways and activated cells mediate the frequently
observed clinical sequelae such as edema, tissue and
organ damage, and hyperfibrinolysis [1]. Among these
potential complications, bleeding is the most frequent
and important. Postoperative hemorrhage is related to
increased morbidity and mortality in patients undergoing
cardiac surgery. Excessive postoperative bleeding has been
attributed to acquired platelet dysfunction, impaired
coagulation, and increased fibrinolysis. The characteriza-
tion of the hemostatic defects responsible for EB is crucial
for specific treatment and optimal clinical management of
the patient [2], however, current risk stratification based
on clinical, procedural, and biological markers is only
partially successful and postoperative bleeding remains a
serious problem for cardiac surgery patients. Major bleed-
ing in cardiopulmonary bypass patients requires higher
amounts of hemoderivatives and is associated with a
higher incidence of reintervention, leading to a higher
morbidity and mortality. When patients undergo reinter-
vention, fewer than 50% exhibit surgical sources of bleed-
ing [3].
Also important in the physiopathology of EB are specific
host factors such as genetic predisposition to bleeding [4-
6] or BMI [7], which may condition the organism's
response to CPB and determine the equilibrium of the dif-
ferent systems activated by CPB.
The aim of this study was to analyze how activated serine
proteases during CPB could be involved with excessive
postoperative bleeding.
Methods
Design and study population
Postoperative care was performed in a polyvalent 24-bed
intensive care unit (ICU), at a University hospital, Canary
Islands (Spain). A total of 50 Caucasian patients undergo-
ing elective CPB were considered for inclusion if they did
not receive antifibrinolytic during or after the surgery,
over a three-month period. Finally, we performed a nested
case-control study of 26 patients who met the criteria. No
patients had a history of hemostatic dysfunction, renal
failure (Cr >2 mg/dL), chronic hepatopathy or immuno-
suppression. Before inclusion the participants had normal
aggregation or coagulation functional test values (bleed-
ing time, collagen/epinephrine and collagen/ADP closure
time, prothrombin time, activated partial thromboplastin
time and thrombin time). None of the patients received
chronical immunosuppressive medications or other anti-
inflammatory agents including acetyl salicylate acid or
clopidogrel during the previous 5 days and the first 24
hours following intervention. This study was approved by
our Hospital Ethics Committee. We obtained informed
written consent from all patients for their inclusion in the
study.
Data collection
Demographic variables, comorbid conditions, periopera-
tive clinical data and postoperative outcomes (duration of
mechanical ventilation, Intensive Care Unit and hospital
stay and mortality) were recorded. Core body tempera-
ture, biochemical determinations (hematology, coagula-
tion, fibrinolysis and complement parameters) and
hemodynamic parameters were recorded at four time
points: before intervention, after surgery at 0 h and at 4 h
and 24 hours post-intervention. In addition, we recorded
blood loss measured by tube chest drainage and the
amount of hemoderivatives used after intervention at the
above time points and when chest tubes were removed
(defined as total blood loss). Excessive bleeding was
defined as blood loss >1 L over 24 hours after interven-
tion. Surgical risk was calculated by parsonnet score and
severity on admission by APACHE-II and SAPS II scores.
Perioperative management
The same anesthetic procedure was used in all patients. All
interventions were performed by the same surgical team.
The extracorporeal circuit consisted of a hardshell mem-
brane oxygenator (Optima XP, Cobe, Denver, Colorado
or Quantum Lifestream International, Inc. TX USA), a
Tygon™ extracorporeal circuit and a Medtronic™ Biopump
centrifugal pump. Under 28–30°C hypothermia, the
pump flow was adjusted to maintain a mean arterial pres-
sure of >60 mmHg and a flow index of 2.2 l/min/m2.
Myocardial protection was achieved using St. Thomas 4:1
sanguineous cardioplegia. The circuit was primed with 30
mg of heparin, followed by an initial dose of 3 mg/Kg and
necessary doses to achieve and mantain an activated clot-
ting time of 480 s. To reverse the effect of heparin, pro-
tamine was used based on blood heparin levels measured
by Hetcon® (HMS.Medtronic™).
Leptin levels
Serum leptin levels (normal range: <50 ng/mL; intra-assay
variation: 3%; inter-assay variation: 6.7%) were measured
using Immunoradiometric Assay (IRMA) (Diagnostic
Division Abbott).
Complement determination
We recorded sequential levels of C3 (normal range 60–
150 mg/dL; intra-assay variation: 1.2%; inter-assay varia-
tion: 1.4%), C4 (normal range: 10–50 mg/dL; intra-assay
variation: 2%; inter-assay variation: 2.5%), C1q (normalJournal of Cardiothoracic Surgery 2007, 2:17 http://www.cardiothoracicsurgery.org/content/2/1/17
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range: 10–25 mg/dL; intra-assay variation: 2.3%; inter-
assay variation: 3.4%), C1 inh (normal range: 15–33 mg/
dL; intra-assay variation: 1.4%; inter-assay variation:
1.8%) and B Factor (normal range: 10–40 mg/dL; intra-
assay variation: 2.2%; inter-assay variation: 3.2%) by
nephelometry, (IMMAGE-Beckman Instruments. Inc.
Fullerton, CA). C7 component (normal range: 4–10 mg/
dL; intra-assay variation: 3%; inter-assay variation: 4.6%)
was determined by radial immunodiffusion.
Coagulation and fibrinolysis determination
Quantitative plasminogen activator inhibitor type-1 (PAI-
1) antigen (normal range: 2–47 ng/mL; intra-assay varia-
tion: 3.7%; inter-assay variation: 4.3%) and tissue plas-
minogen activator (t-PA) antigen (normal range: <9.0 ng/
mL; intra-assay variation: 4.2%; inter-assay variation:
4.0%) were measured using ELISA test (IMUBIND®, Amer-
ica Diagnostica Inc., Stanford, Connecticut, USA). D-
dimer (normal range: <300 ng/mL; intra-assay variation:
3%; inter-assay variation: 3.8%) was measured using
immunoturbidimetric test (D-Dimer PLUS, Dade
Behring, Marburg, Germany).
Gene analysis
Blood samples (3 ml) were collected before surgery in
EDTA-containing tubes and subjected to DNA purifica-
tion using proteinase K, phenol-chloroform extraction,
and ethanol precipitation. Genotyping was performed in
a blinded manner, without knowledge of any clinical
data. Gene analysis of PAI-1G4/G5 polymorphisms was
performed in all patients using primers and restriction
endonuclease digestion. In addition, 22 neutral markers
were genotyped to follow genomic control strategies that
would detect spurious associations due to population
substructure. The neutral markers chosen were Alu repeats
distributed throughout the genome.
Statistical analysis
Pearson's chi2 and Fisher exact test were used, Student t
test for independent groups and Mann-Whitney U test for
non-parametric variables. We compared the ranges of PAI-
1 levels between the different genotypes of PAI-1 poly-
morphism using Jonckheere-Terpstra test. Statistical sig-
nificance was defined as a P-value of less than 0.05. Data
are expressed as median values and interquartile range.
Logistic regression was used for calculating odds ratios
and 95 percent confidence interval between preoperative
PAI-1 levels and excessive bleeding, controlling for BMI
and temperature. Blood loss at 24 hours was log-trans-
formed and an analysis of covariance (ANCOVA) was
used to compare genotypes (5G/5G vs 4G/5G and 4G/4G,
of PAI-1 polymorphisms), controlling for BMI and tem-
perature in two independent models.
Results
EB was observed in 13 out of 26 patients (50%). We
found statistically significant associations between EB and
patients in the lower BMI group <26.4 (25–28) Kg/m2 (P
= 0.03) (Figure 1). Lower preoperative levels of PAI-1 (P =
0.014) were associated with EB. Regarding surgical proce-
dure, EB was significantly greater in those patients who
received internal mammary artery graft (P  = 0.03) in
bypass surgery, and in those who had lower temperature
during cardiopulmonary bypass (P = 0.04).
The distribution of PAI-1 polymorphism was 4G/G in 5
patients (19%), 4G/5G in 12 (46%), and 5G/G in 9
(35%), similar to that observed in 100 consecutive blood
donors from our institution (4G/G: 21%; 4G/5G: 52%;
5G/G: 27%) and was in Hardy Weinberg equilibrium.
With respect to postoperative EB according to PAI-1 poly-
morphism, we observed that 1 out of 5 (20%) of 4G/G
genotype, 5 out of 12 (42%) of 4G/5G and 7 out of 9
(78%) of 5G/G genotype, showed postoperative EB.
Using analysis of covariance (ANCOVA), EB was signifi-
cantly associated with the 5G homozygote for the PAI-1
polymorphism after adjusting for BMI (P = 0.02) and tem-
perature during CPB (P = 0.007). The three genotypes of
PAI-1 polymorphism showed significant differences in
preoperative (Fig 2a) and 0h (Fig 2b) PAI-1 levels, (P =
0.046 and P = 0.018) respectively. 5G/5G patients pre-
sented 24-hour blood loss of 1190 cc (979 cc–1763 cc)
whereas 4G/4G and 4G/5G patients presented 490 cc
(365 cc–605 cc) and 715 cc (475 cc–1175 cc), respectively
(P = 0.021).
EB patients had significant higher consumption of several
components of complement at 0 hours: C1q (P = 0.02),
C1-inhibitor (P = 0.03), B Factor (P = 0.03) and C7 (P <
0.01). At 4 hours these patients had significant lower lev-
els of C1q (P < 0.01), C1-inhibitor (P = 0.04), C3 (P =
0.01), B Factor (P = 0.02) and C7 (P < 0.01).
With respect to coagulation, patients with EB presented
significantly lower levels of prothrombin time (PT) (P =
0.04) at 0 hours, as well as lower levels of PT (P = 0.03)
and fibrinogen (P = 0.03) at 4 hours. Regarding fibrinoly-
sis, we did not find differences in t-PA levels between
groups. However, EB patients showed lower levels of PAI-
1 (P < 0.01) and lower PAI-1/t-PA ratio (P = 0.014) at 0
hours, with higher levels of D-dimer at 4 hours 1015
(944–1177) ng/mL vs 895 (753–905) ng/mL in the non-
EB group (P = 0.18). Serum leptin levels were significantly
lower at all postoperative time points (P = 0.01, P < 0.01
and P < 0.01) in the EB group, which remained significant
after adjusting for BMI (F: 17.5; P = 0.001). They also
showed significantly lower hematocrit levels at 4 h (P =
0.048) and lastly, greater transfusion requirements: totalJournal of Cardiothoracic Surgery 2007, 2:17 http://www.cardiothoracicsurgery.org/content/2/1/17
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red blood cells (P < 0.01) and total plasma (P = 0.047).
See Table 1.
Discussion
In patients who receive prophylaxis against bleeding, the
frequency of excessive bleeding after CPB is around 30%,
depending on the definition used and surgical procedure
[8]. Excessive perioperative bleeding continues to compli-
cate CPB surgery and in some hospitals more than 25% of
all blood products are assigned to open heart surgery [9].
We observed excessive blood loss (>1 L/24 h) in 50% of
the patients after elective cardiac surgery under CPB, none
of whom received antifibrinolytic prophylaxis.
Even when neutral markers partially guarantee genetics
associations, the relationship between 5G homozygosity
of PAI-1 polymorphism and EB must be cautiously con-
sidered given the small sample size.
The PAI-1 4G/5G polymorphism is known to influence
plasma levels of PAI-1, the main regulator of fibrinolysis,
the 4G allele being associated with high levels and the 5G
allele with low levels [10]. Much attention has focused on
the 4G/4G polymorphism; however, there are very few
reports in the literature of the importance of the 5G/5G
polymorphism. In our study, homozygous patients for 5G
presented lower PAI-1 levels preoperatively and at ICU
admission, as well as greater blood loss than other geno-
types. Besides, lower preoperative levels of PAI-1 and
lower ratio PAI-1/t-PA just after surgery might lead to
higher levels of D-dimer later on: this indicates that there
are patients with a lower inhibitory potential for fibrinol-
ysis prior and immediately after surgery, possibly favoring
EB. These patients may benefit from the use of antifibrino-
lytic prophylaxis [11,12].
Within a range of slight overweight, the patients in the
lower BMI group showed EB, a finding which agrees with
those of recently published reports, although the strong
relationship between BMI and excessive bleeding remains
unexplained [7,13]. Obesity is associated with increased
blood concentrations of endothelial dysfunction markers
such as fibrinogen and Von Willebrand factor (vWF) [14],
associated with hypercoagulability [15]. Obesity and
insulin resistance seem to be the most important factors
influencing the level of PAI-1 [16], and on the other hand
the PAI-1 gene polymorphism is known to play a determi-
nant role in the regulation of PAI-1 plasma levels in the
obese, acting at the adipose tissue level [17]. Moreover a
correlation between PAI-1 and leptin has recently been
reported in humans [18]. In our study, leptin levels were
associated with EB. Leptin is the 167-amino acid protein
product of the obese (ob) gene, which is secreted from
adipocytes. Leptin receptors are widely expressed, raising
the possibility that leptin may have broad effects. In fact,
it is now clear that leptin influences a variety of physiolog-
ical and pathological processes including angiogenesis
and vascular disorders. In this regard, leptin-deficient ob/
ob mice, and wild-type mice treated with a leptin-neutral-
izing antibody, develop unstable thrombi and an attenu-
ated thrombotic response to arterial injury, and they
exhibit a defect in platelet aggregation [19,20]. This
underlines the importance of genetic background when
assessing the reaction of an organism to insults, such as
CPB in this case. Nevertheless, data on potential interac-
tions between environmental and metabolic variables on
one hand, and the genetic predisposition on the other, are
still scarce.
Lower core body temperature during CPB and the use of
internal mammary artery graft in cardiac surgery have
been described as risk factors for postoperative bleeding
[7,21].
Excessive bleeding after cardiac surgery is generally related
to a combination of several factors associated with CBP.
Activation of the coagulation cascade gives rise to
thrombin formation which in turn activates the inflam-
matory system, including complement [22]. Activation of
fibrinolysis occurs simultaneously, enhanced by comple-
ment [23]. Complement activation has been associated
with postoperative bleeding and tissue injury [24,25].
This activation occurs during CPB and after neutralization
Horizontal line represents the median, box encompasses the  25th–75th percentile, and error bars encompass the 10th–90th  percentile Figure 1
Horizontal line represents the median, box encompasses the 
25th–75th percentile, and error bars encompass the 10th–90th 
percentile.Journal of Cardiothoracic Surgery 2007, 2:17 http://www.cardiothoracicsurgery.org/content/2/1/17
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of heparin with protamine [26]. In a recent study, fifteen
minutes after heparin reversal, patients were at risk for
excessive bleeding, when enhanced fibrinolysis was
observed [27].
In our study all these alterations were observed in the
patients with excessive postoperative bleeding; at ICU
admission (0 hours) some 20 minutes after heparin
reversal, they showed greater consumption of coagula-
tion, complement and leptin, together with increased
fibrinolysis, as compared to those without EB. These alter-
ations persisted during the first 4 hours after surgery when
the greatest amount of blood loss was recorded. Conse-
quently, EB patients had greater transfusion requirements.
Taking into account the complexity of excessive bleeding
in cardiac surgery with extracorporeal circulation, it is dif-
ficult to establish the relative contribution of each of these
PAI-1 levels according to PAI-1genotypes Figure 2
PAI-1 levels according to PAI-1genotypes. A. Preoperative. B. ICU admission (0-hr).Journal of Cardiothoracic Surgery 2007, 2:17 http://www.cardiothoracicsurgery.org/content/2/1/17
Page 6 of 7
(page number not for citation purposes)
components on the development of this important clini-
cal picture. We consider that the main limitation of the
study is the small sample size, and the findings require
confirmation in larger series.
Conclusion
Excessive postoperative bleeding in CPB patients was
associated with demographics, particularly less pro-





BMI: body mass index.
PAI-1: plasminogen activator inhibitor-1.
IMA: internal mammary artery.
t-PA: tissue plasminogen activator
PT: prothrombin time.
APTT: activated partial thromboplastin time.
Table 1: Characteristics of patients with excessive bleeding vs those withouta
Variables < 1000 cc (n = 13) > 1000 cc (n = 13) P
Demographic
Sex (% males) 6 (46) 9 (69) 0.21
Age (years) 69 (60–75) 64 (61–75) 0.88
Body Mass Index (BMI) (kg/m2) 29.3 (28–32) 26.1 (25–27.9) 0.03
APACHE-II 13 (11–16) 14 (12–18) 0.21
SAPS-II 31 (31–32) 31.5 (29–40) 0.78
Parsonnet 17.5 (13.5–21) 15(9–20.5) 0.55
Surgical parameters
Type of bypass (%) 0.03
Venous 4 (31) 0
Arterial and venous 8 (61.5) 4 (31)
Cardiopulmonary bypass time (min) 85 (77–110) 100 (67–110) 0.84
Aortic clamping time (min) 63 (45–71) 55 (50–70) 0.96
Temperature during CPB (°C) 32 (31.5–32) 31 (30–32) 0.04
Laboratory parameters
C1q 0 h (mg/ml) 10.4(8.7–16.5) 6.9 (6.2–9.1) 0.02
C1q 4 h (mg/ml) 14.9 (9.3–16) 7.6 (7.1–9.8) <0.01
C1q 24 h (mg/ml) 12.8 (9.9–15.6) 8.4 (7.2–10.1) 0.04
C1-Inhibitor 0 h (mg/ml) 20.4 (16.6–21.4) 13.2 (10.4–16.8) 0.03
C1-Inhibitor 4 h (mg/ml) 19.5 (16.2–20.5) 13.2 (10.8–17) 0.04
C4 24 h (mg/ml) 21.2 (17–22.5) 14.7 (13.8–18.8) 0.04
C3 4 h (mg/ml) 87 (76–94) 85(70–88) 0.01
B Factor 0 h (mg/ml) 21.4 (18.9–26.4) 15.6 (15.3–20.2) 0.03
B Factor 4 h (mg/ml) 24.7 (18.7–28.2) 18.6 (17–19.7) 0.02
C7 0 h (mg/ml) 6.3(5.4–8.5) 3.3 (2.5–5.9) <0.01
C7 4 h (mg/ml) 6.6 (5–9.6) 3.3 (2.1–4.6) <0.01
Leptin 0 h (ng/ml) 12.1 (7.5–22.4) 5.5 (1.9–7.7) 0.01
Leptin 4 h (ng/ml) 10.7 (7.8–19.2) 4.2 (1.4–6.2) <0.01
Leptin 24 h (ng/ml) 32.6 (20.4–48.1) 6.9 (3.8–12.3) <0.01
Prothrombin time admission (%) 77 (72–79) 70 (56–71) 0.04
Prothrombin time 4 h (%) 77 (68–81) 67 (64–69) 0.03
Fibrinogen 4 h (mg/ml) 351 (272–409) 272 (209–319) 0.03
Plasminogen activator inhibitor-1 preoperative (ng/ml) 43.5 (31.5–52.8) 25.5 (23–36) 0.01
Plasminogen activator inhibitor-1 0 h (ng/ml) 76.6(53.5–97.3) 35.5 (32.1–42.6) <0.01
PAI-1/t-PA ratio 0 h 3.7 (2.7–6.8) 1.6 (1.2–3.4) 0.014
Hematocrit (%) 4 h 28.6 (25.8–31.9) 25.4 (24–27.8) 0.048
Total red blood cells (ml) 400 (0–800) 1600 (800–2000) <0.01
Total plasma frozen (ml) 0 800 (0–900) 0.047
Blood loss 4 h (mL) 661 (572–992) 220 (170–520) 0.01
Blood loss 24 h (mL) 1190 (978–1762) 605 (470–1100) 0.01
aValues are expressed as median and ranges.Journal of Cardiothoracic Surgery 2007, 2:17 http://www.cardiothoracicsurgery.org/content/2/1/17
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